CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); · Revenue increased to EUR 5.3 billion (+9%, +8% CER[1]) net sales to EUR 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was EUR 1.4 billion (+1%, -4% CER) or 27% of revenue · R&D update: bimekizumab filed with FDA and EMA for psoriasis; timelines for late stage pipeline confirmed - despite pandemic · Financial outlook for 2021: Revenue expected to reach EUR 5.45 - 5.65 billion, adjusted EBITDA[2] 27 - 28% of revenue, Core EPS[3] of EUR 5.60 - 6.10 expected · Outlook 2025: revenue of at least EUR 6 billion and adj. EBITDA margin in the low to mid-thirties BRUSSELS, Feb. 25, 2021 /PRNewswire/ -- "We are very impressed by our employees and partners for their resilience and achievements during 2020. Together we continued to serve patients, took good care of each other and joined forces in the global response to COVID-19. 2020 was another year with good performance in execution of our patient value strategy, ensuring sustained growth for the company also in the longer term," said Jean-Christophe Tellier, CEO UCB. "For the first time we share our growth ambition for 2025, despite upcoming patent expirations. Based on our strong portfolio and the promising late-stage pipeline, we aim to lead in specific populations by 2025, creating value for patients now and into the future. Also, we made progress in the sustainability areas that are critical to our long-term success and our contribution to society."